Frazier Life Sciences Boosts Evergreen Fund with $630M for Small and Mid-Cap Biotechs

Funding Increase:
Frazier Life Sciences has added $630 million to its evergreen public fund, focusing on small and mid-cap biotechs.

Investment Strategy:
The fund aims to capitalize on market volatility to invest in promising biotechnology companies.

Fund Type:
The fund is described as "evergreen," indicating it is a long-only fund that remains open to new investments and does not have a fixed term.

Firm Background:
Frazier Life Sciences is a healthcare investment firm based in Palo Alto, California, with a focus on life sciences and biotechnology investments.

Market Impact:
The additional funding is expected to provide significant support to small and mid-cap biotechs, helping them navigate market challenges and advance their research and development efforts.